Medullary thyroid carcinoma: a 30-year experience at one institution in Korea by 媛뺤긽�슧 et al.
278
pISSN 2288-6575 •  eISSN 2288-6796
https://doi.org/10.4174/astr.2016.91.6.278
Annals of Surgical Treatment and Research
ORIGINAL ARTICLE
Medullary thyroid carcinoma: a 30-year experience at one 
institution in Korea
Cho Rok Lee, Sohee Lee1, Haiyoung Son2, Eunjeong Ban, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong,  
Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Department of Surgery, Yonsei University College of Medicine, Seoul, 1Department of Surgery, The Catholic University of Korea, 
College of Medicine, Seoul, 2Department of Surgery, Catholic Kwandong University International St. Mary's Hospital, Incheon, 
Korea
INTRODUCTION
Medullary thyroid carcinoma (MTC) is a rare endocrine tumor 
that accounts for 5%–8% of all thyroid carcinomas but represents 
up to 13.4% of thyroid cancer­related deaths. MTC derives 
from calcitonin­producing parafollicular C cells of the thyroid 
gland [1,2] and occurs as a sporadic tumor in about 75%–80% 
of those treated and as a hereditary tumor in others (20%–25%) 
[3]. Hereditary MTC is termed multiple endocrine neoplasia 
syndrome (MEN 2A and 2B) [4]. The 10­year disease­specific 
survival rate of MTC is about 75%. The tumor metastasizes 
early to both paratracheal and lateral cervical lymph nodes, 
and distant metastases occur in the liver, lungs, bones, and 
less frequently in brain and skin. Systemic chemotherapy and 
external radiotherapy are of limited efficacy [5,6]. 
A high serum calcitonin (Ct) level is a highly sensitive and 
specific tumor marker for postsurgical follow­up of MTC 
patients after total thyroidectomy. However, in more ad vanced 
tumors, which may dedifferentiated by decreased Ct pro­
duction, CEA may be a more valu able tumor marker [7]. Other 
important prognostic factors for adverse outcome include 
advanced age at diagnosis, extent of primary tumor, and nodal 
metastasis and distant metastases [8]. 
Germ­line point mutations in the RET proto­oncogene are 
responsible for tumor growth and for the heritage setting 
of MEN 2A and 2B [9,10]. RET proto­oncogene mutations of 
activation strength enable risk stratification and may be used to 
individualize treatment plans [8]. To enable early diagnosis and 
treatment, all family members of patients confirmed to have 
MTC should undergo genetic screening. 
Purpose: The objective of this study was to review the clinical outcome and prognosis of patients with sporadic and 
hereditary medullary thyroid cancer (MTC) who were treated at a single tertiary hospital in Korea. 
Methods: We retrospectively reviewed the case files of 85 patients treated from August 1982 to February 2012. 
Results: In all, 65 patients (76.5%) had sporadic MTC and 20 patients (23.5%) had hereditary MTC. Patients in the sporadic 
group were older than in the hereditary group (P < 0.001). However, the hereditary group had more tumor multiplicity (P < 
0.001) and bilaterality (P < 0.001). Neither survival rate was significantly different between the sporadic and hereditary 
groups (P = 0.775 and P = 0.866). By multivariate analysis, distant metastasis was a significant prognostic factor for overall 
and progression-free survival. 
Conclusion: In general, patients with MTC have favorable outcomes. Distant metastasis appears to be the strongest 
predictor of overall and progression-free survival.
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This study evaluated the long­term outcomes of surgically 
treated patients with histopathologically confirmed MTC at a 
single institution of Korea and compared outcomes in patients 
with hereditary and sporadic MTC. The results of RET proto­
oncogene mutation analysis suggest another valid screening 
method for MTC.
METHODS 
Patients and methods 
We retrospectively reviewed the medical records of consecu­
tive patients undergoing surgical intervention for MTC. The 
pa tients were found to have suspicious thyroid nodules after 
palpable neck mass evaluation, medical examination with out 
any symptom, and detection of RET proto­oncogene muta tion 
with thyroid nodules during screening evaluation as a relative 
of MTC patients. Data were retrieved through a thyroid cancer 
database at Severance Hospital and follow­up information was 
obtained through medical record review. The study pro tocol 
was approved by Severance Hospital Review Board. We analyzed 
clinical histories, biochemical evaluations, and histo pathology, 
surgical, and other therapeutic data as well as long­term 
outcomes. Medical histories and RET proto­oncogene mutation 
an alyses were reviewed to determine if the disease was 
sporadic or hereditary. Hereditary MTC was identified on the 
basis of findings of RET proto­oncogene mutation and MEN2 
syndrome. For identification of relevant RET proto­oncogene 
mutations, blood was collected in ethylenediaminetetraacetic 
acid from all subjects. Genomic DNA was purified from 
peripheral blood lymphocytes. The RET proto­oncogene gene 
exons 10, 11, 13, 14, 15, and 16 were analyzed in all index cases 
using polymerase chain reaction and sequencing. Whenever 
the diagnosed RET proto­oncogene point mutation created 
or deleted the recognition site of a restriction enzyme, we 
performed restriction analysis of the mutated exon to confirm 
the presence of RET proto­oncogene mutation. 
Diagnosis and follow-up 
Patients were regarded as having MEN 2A if at least one 
family member had hyperparathyroidism or pheochro­
mocytoma and the specific RET proto­oncogene mutation. 
MEN 2A syndrome can be classified as four variants: (1) 
Classical MEN2A is the most common MEN2A variant in 
which all patients develop MTC, and lower numbers develop 
pheochromocytoma or hyper parathyroidism; (2) MEN2A and 
cutaneous lichen amyloi dosis is a rare disorder; (3) MEM2A 
and Hirschsprung disease (HD) is the third variant; (4) 
familial medullary thyroid car ci noma (FMTC) is the fourth 
variant that is characterized by the presence of an RET proto­
oncogene germline mutation in families with MTC (or single 
individuals with MTC and no family history of MTC) who 
develop neither pheochromocytoma nor hyper para thyroidism 
[4]. Likewise, MEN 2B is considered if one or more family 
member had morphological characteristics of the disease with 
pheochromocytoma and RET proto­oncogene mutation. Sporadic 
cases were defined as patients without pheochromocytoma or 
hyperparathyroidism and no family history of MTC. The diag­
nosis of MTC was based on high serum Ct levels either with 
positive biopsy or fine needle aspiration, thyroid nodules and 
cervical lymphadenopathy, or distant metastases. Diagnosis 
was confirmed by surgical histological results. After surgical 
treatment, we performed regular postoperative workups that 
consisted of at least 6 monthly reviews with physical examina­
tion, measurement of serum Ct and CEA levels, and radiological 
examination (neck ultrasonography, CT, and PET­CT scan). The 
cohort patients were followed until death or the closing date of 
the study. 
Disease recurrence of local area was defined as new evi dence 
of MTC by radiologically and pathologically proven techni­
ques after successful tumor resection. And, the patients were 
regarded to be in biochemical disease (BCD) if Ct levels in­
creased to the normal range and there was no imaging evi dence 
of residual disease at the last follow­up. The normal reference 
value of Ct in our institution is <10 pg/mL. Clinical disease (CD) 
was divided as stable disease (SD) and pro gressive disease (PD). 
At the last follow­up, if there was disease remaining without 
much change from pre treat ment conditions—it was defined 
as SD. And if the disease showed more than a slight increase 
in size or extent on or after treat ment—it was defined as PD. 
Progression­free survival was counted from the time of the 
initial surgery to the first evi dence of recurrence or disease 
progression. 
Statistical analysis 
We used simple summary statistics to describe the demo­
graphic and clinical data, and chi­square and Student t­tests 
for categorical and continuous variable comparisons. Survival 
was estimated by using the Kaplan­Meier method and survival 
curves were compared with the log­rank test using IBM SPSS 
Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). P­values less 
than 0.05 were considered statistically significant.
RESULTS 
Patient demographics and tumor characteristics 
Between January 1982 and February 2012, 141 patients 
underwent thyroid surgery for treatment of MTC at our insti­
tution. Of these, except in the case of lost follow­up and not 
conducting RET proto­oncogene mutation analysis, 85 patients 
were available for this study. The mean age of the 85 patients 
studied was 46.2 years (range, 12 to 80 years). There were 32 
male and 53 female patients. We considered 65 patients (76.5%) 
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to have sporadic MTC. In the remaining 20 patients, MTC 
was a manifestation of either MEN 2A (16 patients) or MEN 
2B (4 patients) syndromes. The mean age of patients in the 
sporadic group was higher than in the hereditary group (50.1 
years vs. 29.9 years, P < 0.001). The male to female ratio of the 
2 groups was not significantly different (1/1.6 vs. 1/2.14, P = 
0.499). The RET proto­oncogene mutation was diagnosed in 6 
patients (9.2%) in the sporadic group and in all patients in the 
hereditary group. Mean tumor size was similar in both groups. 
(1.68 cm vs. 2.15 cm, P = 0.223). Tumor multiplicity and tumor 
bilaterality were higher in the hereditary group than in the 
sporadic group (73.7% vs. 15.4%, P < 0.001, and 78.9% vs. 13.8%, 
P < 0.001). Extracapsular invasion was similar in both groups 
(41.5% vs. 40.0%, P > 0.05). Mean serum Ct level at presentation 
were 1,056.44 ± 2,454.13 pg/mL in sporadic group and 712.22 
± 1,536.37 pg/mL in hereditary group (P = 0.493). Mean CEA 
levels at presentation were similar in sporadic group (110.71 
± 530.39 ng/mL) and in hereditary group (290.63 ±869.40 ng/
mL) (P = 0.303). By the American Joint Committee on cancer 
7th edition TNM staging system, staging distributions for the 
sporadic and hereditary groups were similar (P = 0.580) (Table 1).
Surgical treatment 
Surgical procedures were not uniform. Nearly all patients 
(97.4%, 83 of 85) underwent total thyroidectomy at initial 
surgery. However, 2 patients had less than total thyroidec­
tomy (One patient had thyroid lobectomy for a large benign 
tumor and concurrently pathologically proven occult MTC. 
The other patient had thyroid lobectomy for papillary thyroid 
micro carcinoma but permanent pathology report was changed 
to MTC) and we planned to do no additional completion 
thyroidectomy with the consent of patients. 
A total of 84 patients received central compartment lymph 
node dissection except 1 patient who underwent thyroid 
lobectomy for a large benign tumor and concurrently proven 
occult MTC. In all, 27 patients (31.8%) had modified radical neck 
dissection (MRND) to remove metastatic lymph nodes. Another 
16 underwent MRND for prophylactic cure of lateral neck node 
metastases; however, 1 patient (9.1%, 1 of 11) in the sporadic 
group had occult lateral lymph node metastases (Table 2).
Follow-up results
Mean follow­up period was 76.3 ± 57.0 months (range, 8–251 
months). During follow­up, 13 patients (15.4%) had recurrences (9 
in the sporadic group and 4 in the hereditary group, P = 0.367). 
Seven patients (8.2%) had local recurrence only, 1 patient (1.2%) 
had distant metastasis and another 5 patients (5.9%) had local 
and distant recurrence. Recurrences were treated by reoperation 
(84.6%), chemotherapy (38.5%), radiotherapy (30.8%), and close 
observation (1 patient developed multiple distant metastases 
Table 1. Comparison of clinicopathologic characteristics of sporadic and hereditary medullary thyroid carcinoma in 85 
Korean patients
Variable Sporadic (n = 65) Hereditary (n = 20) P­value
Age (yr) 50.1 ± 11.9 29.9 ± 14.7 <0.001
Sex, male:female 25:40 (1:1.6) 7:13 (1:2.14) 0.499
RET mutation 6 (9.2) 20 (100) <0.001
Tumor size (cm) 1.68 ± 1.34 2.15 ±1.98 0.223
Multiplicity 10 (15.4) 14 (70.0) <0.001
Bilaterality 9/63 (14.3) 15 (75.0) <0.001
Extracapsular invasion 27 (41.5) 8 (40.0) 0.457
Calcitonin at diagnosis (pg/mL) 712.22 ± 1,536.37 1,056.44 ± 2,454.13 0.493
CEA at diagnosis (ng/mL) 110.71 ± 530.39 290.63 ± 869.40 0.303
TNM stagea)
  N stage 0.446
    Nx 1 (1.5) ­
    N0 33 (50.8) 14 (70.0)
    N1a 7 (10.8) 2 (10.0)
    N1b 24 (36.9) 4 (20.0)
  Stage 0.580
    I 34 (52.3) 11 (55.0)
    II 8 (12.3) 4 (20.0)
    III 7 (10.8) 2 (10.0)
    IVA 16 (24.6) 2 (10.0)
    IVB 0 (0) 0 (0)
    IVC 0 (0) 1 (5.0)
Values are presented as mean ± standard deviation or number (%). 
a)TNM stage: 7th edition of the American Joint Committee on cancer TNM staging system.
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and died from intracranial hemorrhage originating from brain 
metastasis [7.7%]). Some patients with recurrences were treated 
with a combination of methods.
In the last follow­up status, 79 patients survived with or 
without disease. A total of 14 patients (11 in sporadic group and 
3 in hereditary group) showed BCD and 6 patients (2 patients 
were SD and 4 patients were PD) showed CD. Fifty­nine patients 
showed no disease. And total of 6 patients (7.1%) had died—4 
deaths (5.1%) were in sporadic group and 2 deaths (10.0%) were 
in hereditary group.
Mean serum Ct level of patients with disease were 326.36 ± 
314.88 pg/mL in sporadic group and 497.48±408.47 pg/mL in 
hereditary group (P = 0.424). And for patients groups without 
disease, the mean serum Ct level were 2.13 ± 1.52 pg/mL in 
sporadic group and 4.59 ± 2.12 pg/mL in hereditary group (P < 
0.000) (Table 3).
The 5­, 10­, and 20­year overall survival rates for the whole 
cohort were 94.3%, 89.6%, and 78.1%, respectively. And the 
5­, 10­, and 20­year overall survival rates were, respectively, 
Cho Rok Lee, et al: Long­term outcome of medullary thyroid carcinoma
Table 3. Follow­up outcomes for medullary thyroid carcinoma 
Variable Sporadic (n = 65) Hereditary (n = 20) Total (n = 85) P­value
Recurrence 9 (13.8) 4 (20.0) 13 (15.4) 0.367
  Local 9 (13.8) 3 (15.0) 13 (8.2)
  Distant 5 (7.7) 1 (5.0) 1 (1.2)
Treatment (multiple)
  Reoperation 8 (88.9) 3 (75.0) 11 (84.6)
  Chemotherapy 4 (44.4) 1 (25.0) 5 (38.5)
  Radiotherapy 3 (33.3) 1 (25.0) 4 (30.8)
  Observation 1 (11.1) 0 1 (7.7)
Status at last follow­up 0.574
  Alive 61 (93.8) 18 (90.0) 79 (94.0)
    With diseasea) 16 (24.6) 4 (20.0) 20 (23.5)
      BCD 11 3 14
      CD (SD) 2 0 2
      CD (PD) 3 1 4
    Without disease 45 (69.2) 14 (70.0) 59 (69.4)
  Dead 4 (6.2) 2 (10.0) 6 (7.1)
  Related to MTC 4 2 6
Calcitonin at last follow­up (pg/mL)
  With disease 326.36 ± 314.88 497.48 ± 408.47 371.39 ± 397.46 0.424
  Without disease 2.13 ± 1.52 4.59 ± 2.12 2.59 ± 1.89 <0.001
Overall survival (%) 0.775
  5 Years 96.3 88.8 94.3
  10 Years 90.7 88.8 89.6
  20 Years 72.2 88.8 78.1
Progression­free survival (%) 0.866
  5 Years 85.6 75.1 82.5
  10 Years 62.4 75.1 66.1
  20 Years 34.2 75.1 22.3
Values are presented as number (%) or mean ± standard deviation.
BCD, biochemical disease (detected calcitonin but no clinical disease); CD (SD), clinical disease (stable disease); CD (PD), clinical 
disease (progressive disease); MTC, medullary thyroid cancer.
a)With disease: biochemical disease, clinical disease. 
Table 2. Types of primary surgery for medullary thyroid car­
cinoma
Primary operation Sporadic  (n = 65)
Hereditary (n = 20)
MEN IIa  
(n = 16)
MEN IIb  
(n = 4)
Thyroid
  Less than total thyroidectomy 2 (3.1) 0 (0) 0 (0)
  Total thyroidectomy 63 (96.9) 16 (100) 4 (100)
Lymph node 
  Therapeutic MRND 23 (35.4) 3 (20) 1 (25)
  Unilateral 15 0 0
  Bilateral 8 2 1
  Mediastinum 0 1 0
Prophylactic MRND 11 (16.9) 4 (20) 1 (25)
  Unilateral 5 3 1
  Bilateral 6 1 0
  Occult metastasis 1/11 (9.1) 0/5 (0)
MEN, multiple endocrine neoplasia syndrome; MRND, modified 
radical neck dissection.
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96.3%, 90.7%, and 72.2% in the sporadic group and 88.8%, 
88.8%, and 88.8% in the hereditary group. The Kaplan­Meier 
curves of overall survival of the sporadic and hereditary groups 
are shown in Fig. 1. The 5­, 10­, and 20­year progression­free 
survival rates for the whole cohort were 82.5%, 66.1%, and 
22.3%, respectively. And the 5­, 10­, and 20­year progression­free 
survival rates in the sporadic group were, respectively, 85.6%, 
62.4%, and 34.2% and in the hereditary group were 75.1% (Fig. 
2). There were no significant differences between the groups in 
overall and progression­free survival (P = 0.775 and P = 0.866, 
respectively).
By multivariate analyses, only distant metastasis was a signi­
fi cant predictor of overall survival. Tumor size, lymph node 
metastasis, and distant metastases remained statistically signi­
fi cant predictors of disease­free survival. The hazard ratios asso­
ciated with the predictor variables in the multivariate analysis 
are summarized in Table 4. 
RET proto-oncogene mutation analysis 
Of the 141 patients who underwent thyroid operations in 
the study institution from January 1982 to February 2012, 
20 were lost to follow­up and another 36 refused genetic an­
alysis. Twenty­six (30.6%) of the remaining 85 patients who 
had genetic analyses were found to have RET proto­oncogene 
mutation. Six patients with sporadic MTC and 20 patients 
with hereditary MTC had RET proto­oncogene mutations. For 
the RET proto­oncogene genetic screening analysis for family 
members, 58 of the index patients participated in the genetic 
analysis. Of these, 26 (44.8%, 26 of 58) had RET proto­oncogene 
mutations. In the sporadic group (6 patients), mutations were 
found at codons 618, 631, 768, and 790. In the 15 MEN 2A 
patients, mutations were documented at codons 611 and 634. 
All 4 patients with MEN 2B had mutations found at codon 918. 
Codon 600 mutations were found in one familial MTC patient 
(Fig. 3, Table 5). Among the 26 family members, 6 relatives with 
634 mutations underwent thyroidectomy for treatment of MTC. 
And the last members were recommended for regular follow­up 
with neck ultrasonography in our institution or other hospital. 
DISCUSSION 
MTC, a rare thyroid malignancy, that represents less than 
10% of all thyroid cancers, has a different clinicopathologic 
behavior than such malignancies as papillary and follicular 
cancer. It secretes Ct and may occur either as a hereditary or 
a nonhereditary entity. MTC occurs about 75%–80% of the 
time as a non­hereditary (sporadic) tumor and 20%–25% as 
a hereditary tumor [2,3]. In this study, 65 patients (76.5%) 
had the sporadic form of the disease and 20 patients (23.5%) 
had a hereditary type. Usually in sporadic MTC, the tumor is 
unifocal and diagnosed in the fifth or sixth decade of life. In 
the hereditary type, most patients are asymptomatic at dis­
co very and diagnosed by genetic or biochemical screening 
tests during the early stages of the disease. The clinical 
mani festations of sporadic MTC include a thyroid nodule or 
mass, cervical lymphadenopathy or other cervical symptoms, 
meta static disease, and rarely diarrhea, flushing, or Cushing 
syndrome due to chronic ectopic adrenocorticotropic hormone 
production. Hereditary MTC usually has both multifocal and 
bilateral disease [11]. In this study, hereditary group showed 
apparently higher rates of tumor multiplicity and bilaterality 
compared with sporadic group and younger age than those in 
the sporadic group. In TNM stage classification, about half of 
the patients belonged to early stage, and TNM stage analyses 
were not statistically different between the 2 groups. We 
believe that frequent screening with newer techniques such as 
neck ultrasound examinations and preoperative fine needle 
aspiration biopsies is leading to earlier diagnosis of MTC. 
Biochemical and genetic screening would also help detect 
persons with early stage sporadic MTC. Furthermore these 
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advances could also affect the outcome of persons with here­
ditary MTC. 
The initial treatment of both hereditary and sporadic forms 
of MTC is total thyroidectomy and removal of all neoplastic 
tissue present in the neck. Many studies have reported that 
survival of MTC patients is dependent upon the adequacy of the 
initial surgical procedure [12,13]. At diagnosis, MTC commonly 
is accompanied by cervical lymphadenopathy. In this study, 
the prevalence of lymphadenopathy was 36.9% in the sporadic 
group and 25.0% in the hereditary group. Others have reported 
prevalence of 20% to 72% [14,15]. During the early years of this 
study, the hospital’s surgical approach was not standardized. 
However, since the early 1990s, total thyroidectomy and 
prophylactic or curative central compartment lymph node 
dissection has been used. We performed prophylactic MRND in 
16 patients, however only 1 (9.1%) had proven lateral neck node 
metastases. Patients without suspected lateral lymph node 
metastases in image studies and with high serum Ct levels 
underwent prophylactic MRND. Some studies favor prophylactic 
lateral neck dissection in patients with large tumors (>1 cm) 
and in genetic carriers detected through prospective family 
screening or by high preoperative serum Ct levels [13]. We 
were unable to study the efficacy of prophylactic lateral neck 
dissection in this study, which should be considered in future 
studies. 
When possible, re­operation is the main treatment for local 
and regional MTC recurrence. For management of distant 
metastases, surgery may be indicated when a single or few 
metastases are located in the brain, lung, or liver [2]. Of the 
patients in this study, some had reoperation of local and 
regional recurrent lesions; others had systemic chemotherapy 
and radiotherapy. Distant metastases are the main cause of 
death of MTC patients. Survival after the discovery of distant 
metastases is 51% at 1 year, 26% at 5 years, and 10% at 10 years 
[5,16,17]. In our study, survival rates after the discovery of 
distant metastases was similar (76.8% at 1 year; 40% at 5 years).
The long­term overall survival and progression­free survival 
rates in our cohort were similar to other recent studies: overall 
survival rates of 94.3%, 89.6%, and 78.1% at 5, 10, and 20 years, 
respectively, and progression­free survival rates of 82.5%, 66.1%, 
Table 5. RET proto­oncogene genetic screening results
Codon 
Patients Family 
members  
(n = 26)
Total  
(n = 52)Sporadic  
(n = 6)
Hereditary  
(n = 20)
600 0 1 (FMTC) 13 14
611 0 1 (MEN 2A) 2 3
618 3 ­ 0 3
631 1 0 0 1
634 0 14 (MEN 2A) 11 25
768 1 ­ 0 1
790 1 ­ 0 1
918 0 4 (MEN 2B) 0 4
FMTC, familial medullary thyroid carcinoma; MEN, multiple 
endo crine neoplasia syndrome.
141 MTC patients*
20 Patients
(lost to follow-up)
121 atientsP
36 atients
(refused genetic screening)
P 85 atients
(RET mutation analysis)
P
26 atients
(diagnosed RET mutation)
P
58 Family members
(RET mutation analysis)
26 Members
(diagnosed RET mutation)
Fig. 3. RET proto­oncogene ge­
ne tic screening and counseling. 
*Pa tients underwent thyroid op­
e ra tion from January 1982 to 
February 2012.
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and 22.3% for the same periods [17­20]. Long­term survival of 
the two types of MTC patients was not significantly different. 
Numerous parameters have been proposed as prognostic factors 
for the outcome for patients with MTC. Age at diagnosis, TNM 
stage and completeness of initial surgery are significant factors 
related to outcome [5,14,17]. Although many studies note a less 
favorable prognosis of sporadic MTC compared with hereditary 
MTC due to disease presentation at an advanced stage 
[16,17,21,22], others, after controlling for disease stage, found 
that type of MTC was not an independent prognostic factor 
[5,18,23]. In our cohort, tumor size, extracapsular invasion, 
lymph node metastasis, and distant metastases through 
disease course remained significant independent indicators 
of progression­free survival. For overall and progression­free 
sur vival, the presence of distant metastases was especially im­
por tant, but the type of MTC was not significant for long­term 
sur vival. 
Germline RET proto­oncogene mutations are observed 
in 98% of MEN 2A, in 95% of MEN 2B, and in 88% of FMTC 
patients. These are crucial for the onset and progression of 
MTC in patients with the hereditary form of the disease 
[9,24]. The American Thyroid Association has developed an 
MTC risk stratification index based on genotype of RET proto­
oncogene mutations and this system is used to individualize 
the aggressiveness of treatment. Therefore, once a germline RET 
proto­oncogene mutation has been identified in a family, RET 
proto­oncogene mutation analysis should be done for all first­
degree relatives of known mutation carriers [8]. About 4%–10% 
of patients with sporadic type MTC have germline mutations of 
the RET proto­oncogene [25,26]. While the somatic RET proto­
oncogene mutation rate has been reported to vary from 12% to 
100% in many studies, the frequency and prognostic correlation 
of RET proto­oncogene somatic mutations in sporadic 
MTC remains controversial [27­30]. Our institution actively 
recommends RET proto­oncogene analysis of persons with 
sporadic MTC; however, before sug gesting the genetic analysis, 
we must consider the problems of expense and the reluctance 
of Koreans to have genetic screening.
In this study, the most common mutations of index patients 
were found in codons 634 and the codon 600 mutation was 
most common in genetic screening analysis of relatives of index 
patients. With the use of active genetic counseling and genetic 
mutation analysis, we identified persons with occult hereditary 
MTC and recommended prophylactic or curative thyroidectomy 
adjusted to their risk stratification. 
This study evaluated genetic mutation status and long­term 
follow­up in MTC patients at a single institution in Korea. We 
also analyzed RET proto­oncogene mutation status of their 
relatives as found by genetic screening. The incidence of MTC 
at our institution over about 30 years was 0.85% (among 16,500 
patients who underwent thyroid surgery for thyroid carcinoma 
during this period). Introduction of RET proto­oncogene 
mutation analysis could lead to improved outcomes in patients 
detected by screening. Some patients in our institution were 
diagnosed by genetic screening as having RET proto­oncogene 
mutation and were subsequently treated for MTC. There was 
a 1­year­old patient that had a codon 918 mutation detected by 
genetic screening and underwent prophylactic thyroidectomy. 
His final pathology result was only c­cell hyperplasia and he has 
had no disease during ten years of follow­up. Unfortunately, we 
were unable to evaluate any relationship between the genotype 
and phenotype when treating these inherited malignancies. 
Due to a low incidence rate of MTC in Korea, there has been 
no systematic study of MTC in Korea. Therefore, multicenter 
studies would be required to verify any genotype­phenotype 
correlation. Nevertheless, patients with RET proto­oncogene 
mutation in sporadic type MTC should be closely followed and 
advised about associated endocrine abnormalities and disease 
risk for family members. 
This study analyzed patients with MTC who had long­term 
follow­up. Most patients had favorable remission rates and long­
term outcomes. Long­term survival was similar for persons with 
sporadic and hereditary MTC. Distant metastases appeared to 
be the strongest predictor of overall and disease­free survival 
followed by tumor size and lymph node metastasis. Earlier diag­
nosis, complete surgical resection of tumor foci and appropriate 
genetic counseling with genetic screening are essential to 
improve the outcome of persons with MTC. 
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